Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Alexis Brown

Physician Assistant Allentown, PA Physician Assistant

NPI 1700333739 CMS profile 10724201

1250 S Cedar Crest Blvd, Allentown, PA 18103

Open in the dashboard

General payments

$5,054

101 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexis Brown of Allentown, PA is reported in the CMS Open Payments database as having received $5,054 across 101 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $313 4
2024 General $92 5
2023 General $652 22
2022 General $507 33
2021 General $3,490 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexis Brown
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Alexis Brown were reported at $313. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Alexis Brown Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $3,490 $132 $37–$438 $132
2022 $507 $155 $48–$522 $149
2023 $652 $167 $52–$557 $160
2024 $92 $178 $55–$600 $164
2025 $313 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Ethicon Inc. $2,876 10 payments
  2. Astellas Pharma US Inc $395 26 payments
  3. Boston Scientific Corporation $308 10 payments
  4. AstraZeneca Pharmaceuticals LP $299 12 payments
  5. Teleflex LLC $150 2 payments
  6. Myovant Sciences Inc. $133 2 payments
  7. Photocure Inc $125 2 payments
  8. Globus Medical, Inc. $123 1 payment
  9. Blue Earth Diagnostics Limited $119 7 payments
  10. Olympus America Inc. $89 5 payments
  11. Other $437 24 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,312 95 payments
  2. Consulting Fee $1,960 1 payment
  3. Travel and Lodging $709 4 payments
  4. Education $73 1 payment
Products named General payments · program years 2021–2025
  1. Monarch Platform $2,876 10 payments
  2. LYNPARZA $299 12 payments
  3. MYRBETRIQ $244 19 payments
  4. General - Kidney Stone Disease $220 5 payments
  5. XTANDI $171 12 payments
  6. UROLIFT $150 2 payments
  7. ORGOVYX $133 2 payments
  8. Cysview $125 2 payments
  9. Anthem $123 1 payment
  10. Axumin $69 4 payments
  11. Other $683 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,126

Median for Physician Assistant: 241

Drug cost

$84,775

Median for Physician Assistant: $4,110

Branded share of claims

33.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 56 $47,032
Potassium Citrate Er Potassium Citrate Brand 114 $15,157
Tamsulosin Hcl Generic 354 $8,522
Renacidin Citric Ac/Gluconolact/Mag Carb Brand 12 $5,879
Trospium Chloride Generic 33 $2,983
Finasteride Generic 59 $938
Oxybutynin Chloride Er Oxybutynin Chloride Brand 46 $901
Oxybutynin Chloride Generic 14 $804
Cephalexin Generic 84 $570
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 23 $399

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$52,192

Medicare's payments for the services billed

Medicare patients

503

Average age 73

Services billed

956

206 women, 297 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Chronic kidney disease 41%
Diabetes 39%
Ischemic heart disease 31%
Depression 27%
Atrial fibrillation 25%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

101 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record